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Abstract
Background and aim: Despite recent publications, practitioners remain unfamiliar with the current terminology
related to the placebo and nocebo phenomena observed in clinical trials and practice, nor with the factors that
modulate them. To cover the gap, the European Headache Federation appointed a panel of experts to clarify the
terms associated with the use of placebo in clinical trials.
Methods: The working group identified relevant questions and agreed upon recommendations. Because no data
were required to answer the questions, the GRADE approach was not applicable, and thus only expert opinion was
provided according to an amended Delphi method. The initial 12 topics for discussion were revised in the opinion
of the majority of the panelists, and after a total of 6 rounds of negotiations, the final agreement is presented.
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Results/recommendations: Two primary and mechanism-based recommendations are provided for the results of
clinical trials: [1] to distinguish the placebo or nocebo response from the placebo or nocebo effect; and [2] for any
favorable outcome observed after placebo administration, the term “placebo response” should be used, and for any
unfavorable outcome recorded after placebo administration, the term “nocebo response” should be used (12 out of
17 panelists agreed, 70.6% agreement). The placebo or nocebo responses are attributed to a set of factors including
those that are related to the medical condition (e.g. natural history, random comorbidities, etc.), along with
idiosyncratic ones, in which the placebo or nocebo effects are attributed to idiosyncratic, or nonspecific
mechanisms, exclusively (e.g. expectation, conditioning, observational learning etc.). To help investigators and
practitioners, the panel summarized a list of environmental factors and idiosyncratic dynamics modulating placebo
and nocebo effects. Some of them are modifiable, and investigators or physicians need to know about them in
order to modify these factors appropriately to improve treatment. One secondary recommendation addresses the
use of the terms “placebo” and “nocebo” (“placebos” and “nocebos” in plural), which refer to the triggers of the
placebo/nocebo effects or responses, respectively, and which are inert agents or interventions that should not be
confused with the placebo/nocebo responses or effects themselves (all panelists agreed, 100% agreement).
Conclusion: The working group recommends distinguishing the term response from effect to describe health
changes from before to after placebo application and to distinguish the terms placebo(s) or nocebo(s) from the
health consequences that they cause (placebo/nocebo responses or effects).
Keywords: Placebo, Placebo response, Placebo effect, Nocebo, Nocebo response, Nocebo effect
Introduction
The terminology surrounding placebo and nocebo research
is not yet familiar to practitioners and trialists. In addition,
researchers in the field are using the related terms in a dif-
ferent way. Besides the recent consensus on the clinical im-
plications of placebo and nocebo effects for clinical practice
[1], there are still unanswered questions related to placebo
and nocebo response and effect, as well as to the exact
meaning of the term “placebo” and “nocebo”. For example,
it is not yet clear whether the adverse events (AEs) recorded
in the placebo-treated arm of a clinical trial, should be
called nocebo response or nocebo effect. Others introduced
the term “drucebo” (a combination of DRUg and plaCEBO
or noCEBO) to relate to a favorable or unfavorable out-
come which results from the patients’ expectation exclu-
sively and is not pharmacologically caused by the
medication [2]. Introducing new terms may generate more
confusion, however. To address this issue, the European
Headache Federation appointed a panel of experts by
recruiting researchers in the field of placebo, clinicians and
pharmacologists to further clarify the terms related to the
placebo administration in clinical science.
Methods
Twenty investigators were approached and 18 agreed to
participate in the working group (90% participation rate).
The composition of the task force was based on the fol-
lowing criteria: researchers focused on placebo or
nocebo research (17 approached, two declined to partici-
pate), clinicians with relevant work (two members, DDM
and PPS) and a member of the Executive Board of the
EHF (AMB). Because no data were required to answer
the questions, the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
was not applicable, and thus only expert opinion was
provided. The agreement process was performed accord-
ing to the Delphi method [3]. The co-chairs (DDM and
FB) arranged 12 relevant topics for discussion (Table 1)
shared by email with the members of the working group.
In each email round, panelists were instructed not to
discuss among themselves and to send their feedback
only to the facilitator (DDM). The facilitator collected all
the answers and issued for each round a report with
comments together with the co-chairman (FB). Six con-
secutive drafts of the recommendation manuscript were
prepared and reviewed by all authors. Based on their
comments and suggestions drafts 1 and 5 were edited
(rounds 2 and 6). The final manuscript (round 7) drafted
by the chairs of the panel (DDM and FB) and was
reviewed by all members of the panel for final approval.
RESULTS and RECOMMENDATIONS
The 12 initial topics for discussion with the relevant de-
cisions and proportion of agreement are presented in
Table 1. All panelists agreed with the final recommenda-
tion, except for distinguishing the terms placebo/nocebo
response from placebo/nocebo effect (70.5% agreement).
One panelist left the panel due to disagreement over the
definition of placebo response and placebo effect. The
working group agreed upon the following definitions.
Placebo (placebos, plural)
Substances and interventions are considered placebos when
they lead to a beneficial outcome after administration or
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application, although their active ingredients lack this po-
tential. Active ingredients include pharmacologically active
compounds, properties, psychological interventions, phys-
ical manipulations and other (e.g. sham surgery, sham
stimulation, etc.).
Comments
1. Placebo is a substance or an intervention and should
be distinguished from the placebo response that
includes any health change from before to after the
placebo administration or application, as well as the
placebo effect which includes health changes related
to the placebo mechanisms exclusively (see below).
2. A placebo is not only the inert treatment, or the
intervention per se, but also any signal from the
surrounding context that accompanies the
therapeutic ritual/act. Stimuli from the
environment that have been shown to modify the
consequences of the placebo administration and/or
application are listed in appendix.
3. Placebos (or placebo agents/interventions) are
administered in research and clinical settings either
to create a positive expectancy and subsequent
health improvement or to validate a new treatment/
intervention in clinical trials.
4. Any health change occurring in a placebo treated
group of participants in the context of a clinical
trial, also occurs in the active treatment group, in
addition to the potential effect of the active
ingredient. Therefore, placebos should always be
indistinguishable by both the investigator and the
trial participant in clinical trials (notwithstanding
that this aim may sometimes not be achieved).
5. A scientifically supported treatment could be a placebo
when given for an unrelated condition (e.g. an antibiotic
prescribed for a viral illness), thus placebos are relative
to a particular patient and a particular disorder.
6. Any substance or intervention that is offered to a
patient or a volunteer by informing him/her that a
potential beneficial treatment is being delivered serves
as placebo as well, in addition to any other biological
effect related to the pharmacological properties of the
substance or the physical manipulations. This explains
why placebos are present in clinical practice, when a
physician recommends a treatment.
7. Positive information frommedia may also serve as a placebo.
Placebo response
The placebo response refers to any beneficial conse-
quence of a therapeutic act (e.g., differences in symp-
toms from before to after treatment), which is made up
of any cue in the surrounding context, and informing
the patient or the volunteer that a potential beneficial
treatment is being delivered. The placebo response con-
sists of any favorable health change occurring from be-
fore to after a placebo administration or application (i.e.,
differences in symptoms from before to after treatment),
thus including the natural history of the medical condi-
tion investigated, the regression of the medical condition
to the mean along with those changes that are attributed
to the placebo mechanisms exclusively (see below).
Comments
1. Placebo responses are recorded in research and
clinical settings to either investigate the phenomenon
or to validate a new treatment/intervention.
2. In clinical trials the beneficial outcomes seen after
administration of a placebo, should be called placebo
response, which also includes the placebo effect.
Placebo effect
A placebo effect refers to those particular beneficial health
changes that are observed after a placebo administration
or application, which are attributed to the placebo mecha-
nisms exclusively, e.g. expectation, conditioning, observa-
tional learning.
Table 1 The 12 initial topics for discussion with the relevant
decisions and proportion of agreement
1. Definition of placebo (placebos, plural). All panelists agreed to include
this topic, and all agreed to the recommended definition.
2. Definition of placebo phenomenon. 15 out of 17 panelists agreed to
withdraw this term in order to avoid further confusion.
3. Definition of nocebo (nocebos, plural). All panelists agreed to include
this topic, and all agreed to the recommended definition.
4. Definition of nocebo phenomenon. 15 out of 17 panelists agreed to
withdraw this term in order to avoid further confusion.
5. Should we distinguish the placebo or nocebo response from the
placebo or nocebo effect and why? All panelists agreed to include this
topic; 12 out of 17 panelists agreed to distinguishing the two terms.
6. Placebo response definition. All panelists agreed to include this topic,
and all agreed to the recommended definition.
7. Placebo effect definition. All panelists agreed to include this topic,
and all agreed to the recommended definition.
8. Nocebo response definition. All panelists agreed to include this topic,
and all agreed to the recommended definition.
9. Nocebo effect definition. All panelists agreed to include this topic,
and all agreed to the recommended definition.
10. Should we use the term placebos or nocebos to include both
placebo/nocebo responses and effects? All panelists agreed to include
this topic, and all agreed to distinguishing the two terms.
11. Are placebo and nocebo phenomena cognitive-like functions? 15
out of 17 panelists agreed to withdraw this topic because it was not fit-
ted to the aim of the working group.
12. Are there animal and human models for placebo and nocebo? 15
out of 17 panelists agreed to withdraw this topic because it was not
fitted to the aim of the working group.
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Comments
1. The placebo effect is better studied in human
studies, although animal studies may help elucidate
some of the mechanisms, for example conditioning,
particularly pharmacological conditioning.
2. The placebo effect is calculated as the difference between a
placebo or nocebo treated group/condition and a no-treated
group/condition as this is the basis for deriving mechanisms.
Nocebo (nocebos, plural)
Substances and interventions are considering nocebos
when they lead to a negative outcomes after administra-
tion or application, although their active ingredients lack
this potential. Active ingredients include pharmacological
properties, psychological effects or physical manipulations.
Comments
1. Nocebos are purposefully applied only for research
to create a negative expectancy and outcome in
order to investigate the origin of nocebo
phenomenon. However, nocebos can also be found
in clinical research and routine medical practice.
For example, the safety information delivered by the
investigators to the participants of a clinical trial or
the AEs listed in the leaflet of drug packages, may
induce negative expectations serving as nocebos.
2. Like placebo, nocebo is characterized by the
surrounding context that consists of any stimulus
or information from the environment (appendix).
Nocebo response
The nocebo response refers to any unfavorable conse-
quence of a therapeutic act (e.g., differences in symptoms
from before to after treatment), which is made up of any
cue in the surrounding context, and informing the patient
or the volunteer that a negative outcome may occur. Thus,
nocebo response includes the natural history of the medical
condition in question, spontaneous worsening of the symp-
toms, as well as random comorbidities, among several other
components that are attributed to the nocebo effect.
Comments
1. To investigate or observe a nocebo response the
administration of a nocebo is required. A nocebo
response may occur unintentionally as well.
2. Assessing the AEs, or any unfavorable outcome, in
patients who are treated with placebo, monitors the
nocebo response in clinical trials.
3. Nocebo response is associated with lower
adherence to the therapeutic intervention and
higher rates of treatment withdrawal [4].
Nocebo effect
The nocebo effect refers to those particular unfavorable health
changes that are observed after a nocebo administration or ap-
plication which are attributed to the nocebo mechanisms ex-
clusively, e.g. expectation, conditioning, observational learning.
The effect - response controversy
Not all panel members agree on the terminology suggested.
One researcher (IK) use the terms “placebo/nocebo response”
and “placebo/nocebo effect” in the opposite way [5]. In a re-
cent position paper from the European Academy of Allergy
and Clinical Immunology, the term “placebo effect” was de-
fined as “the psychological and physiological benefits of seek-
ing advice and receiving treatment for a medical problem,
independently of the prescribed treatment’s pharmacological
effects per se” [6]. Historical and traditional reasons may ex-
plain the differences. Here, the vast majority of panelists
agreed on the recommended terminology, and, eventually, this
is an area that needs to be ironed out in future research.
Clinical implications
Should we distinguish the placebo or nocebo response
from the placebo or nocebo effect in clinical trials and
why?
Introduction
Most panelists declare there is a significant difference be-
tween the two terms, but not all agree. There is no agree-
ment for the rationale as well. Defenders say that the
distinction is important for the same reason that it is im-
portant to distinguish between a drug response and a drug
effect, with the drug effect as the difference between the
drug response and the placebo response. “A drug response
is the change that occurs after administration of the drug.
The effect of the drug is that portion of the response that
is due to the drug’s chemical composition; it is the differ-
ence between the drug response and the response to pla-
cebo.” [7]. However, in clinical trials both treatment
response and treatment effect are collectively used as
treatment efficacy reflecting the expected effect size of the
treatment in practice. In analyses of clinical trials another
metric is used, the “therapeutic gain” representing the dif-
ference of the outcome between active and placebo-
treated groups [8]. Another metric is the absolute differ-
ence between active drug and placebo-treated arms,
known as number-needed to treat [9] and the relative effi-
cacy of the treatment, or the relative risk reduction as
measures of treatment effect size [10], or both [11]. The
terms “treatment response” and “treatment effect” have
very limited use in the literature currently, at least in the
field of neurology and headache. Therefore, distinguishing
placebo response from placebo effect remains controver-
sial for clinical science. On the other hand, all panelists
considered it necessary to distinguish placebo/nocebo re-
sponses from placebo/nocebo effect in order to investigate
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underlying potential mechanisms. Thus, the final recom-
mendation is mechanism-based.
Recommendation
We recommend distinguishing the two terms (response
from effect) because their mechanisms are different. This
distinction is crucial for the research (experimental human
studies), but may also help practitioners to better interpret
the trial results and to modify their practice in order to
limit the modifiable nocebo factors listed in appendix.
What should we call the efficacy and the adverse events
recorded in the placebo arms of a clinical trial?
Introduction
A systematic review of clinical trials concluded that the me-
dian prevalence of AEs in placebo groups was 49.1% (IQR
25.7–64.4%), and the median rate of dropouts due to AEs
was 5% (IQR 2.28–8.4%) [12]. There is therefore a question
of terminology regarding the AEs recorded in placebo arms.
Most panelists agree that the term “response” better de-
scribes the favorable and unfavorable outcomes observed
after placebo administration in clinical trials.
Recommendation
According to the terminology of placebo response, the
beneficial outcomes seen in a placebo-treated arm of a clin-
ical trial should be called placebo response. In the same
way, any unfavorable outcome seen in the placebo-treated
arms of clinical trials should be called nocebo response.
Environmental stimuli influencing placebo and nocebo
responses in clinical trials and practice
The surrounding context that potentially modifies placebo
and nocebo responses in clinical science and practice con-
sists of any stimulus or information from the environment
(e.g. media, internet, health setting); the treating medical
and paramedical personnel or researcher (including the
symbols, rituals, and verbal and nonverbal expressions
and communications they employ); the patient’s medical
condition, or the rationale for the experiment; and the ex-
pectations and prior experiences of the patient or volun-
teer that may vary over time or by education; and the
price of a medication or the label on the box, etc. In a clin-
ical trial these factors are, presumably, essentially the same
for both the control and verum conditions. And, of course,
these same factors are also operative in ordinary clinical
practice. In Appendix, a list of these stimuli is presented,
divided into modifiable and non-modifiable ones.
Conclusions
Treatment outcomes are not exclusively attributable to
the biological or physical mechanisms of action of the
therapeutic interventions per se, but additional environ-
mental, random or idiosyncratic variables are also
components of the final result. To better understand
and investigate this impact a mechanism-based approach
is needed. Therefore, to measure the effect size of a
treatment that can be attributed exclusively to the mech-
anism of action of the treatment in question, testing in
parallel with an inert treatment is essential. This inert
treatment whether it is an agent, a manipulation, a sham
stimulation or an inert intervention, should be called
placebo. To interpret the consequences of placebo ad-
ministration or application in clinical trials two terms
have been in use, the placebo response and the placebo
effect. However, these terms have different meanings,
refer to different elements and are powered by different
mechanisms. This panel of experts, on behalf of the
European Headache Federation, aiming to clarify these
terms in order to help clinicians and trialists to better
interpret the trials’ results, recommends distinguishing
the term response from effect, using the term placebo re-
sponse to describe any favorable outcome observed from
before to after placebo administration, and nocebo re-
sponse to describe any unfavorable outcome observed
from before to after placebo administration. Several ran-
dom variables, such as accidental deterioration or im-
provement in the condition, or accidental involvement
with another condition along with idiosyncratic variables
that are linked to placebo or nocebo mechanisms are
components of the placebo or nocebo responses, while
the placebo and nocebo effects refer to those favorable or
unfavorable outcomes observed from before to after a
placebo application that are powered by the patient
mind entirely, e.g. conditioning, expectations, observa-
tional learning, etc.
In human experimental studies, to induce negative out-
comes and investigate their underlying mechanisms, inert in-
terventions are administered to participants. These inert
agents or interventions that cause unfavorable outcomes al-
though their active ingredients lack this potential, are called
nocebos. Like placebos, nocebo responses should be distin-
guished from nocebo effects. In clinical trials there is no direct
nocebo application, yet the safety information delivered by the
investigators may serve as a nocebo in both arms and may in-
duce AEs that cannot be separated from the drug-related
ones. To limit nocebo effects, appropriate modification of the
informed consents currently used may be required.
In clinical practice, placebos and nocebos are rarely
explicitly administered. However, environmental infor-
mation, including any stimuli from the entire therapeutic
encounter may serve as placebo or nocebo, e.g. the drug
or device packaging, color, price, the setting of the med-
ical unit, the patient-doctor relationship and clinician
communication style, etc. Physicians should be aware of
these variables in order to devise strategies for each indi-
vidual patient that limit nocebo and increase placebo ef-
fects to improve treatment outcomes for the patient.
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